Skip to contentI
IDEAYA Biosciences, Inc.
I
IDYAIDEAYA Biosciences, Inc. Q2 2023 · 10-Q
Revenue$3.54M$3.54M−39.4% vs Q2 2022 Net Income-$27.93M-$27.93MN/M vs Q2 2022 EPS Diluted-$0.50-$0.50N/M vs Q2 2022 Operating Income-$32,709,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IDEAYA Biosciences, Inc. · CIK 1676725 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$34,344,000N/M Margins · derivedOperating margin-922.9%−538.4 pt vs Q2 2022
Net margin-788.0%−411.0 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 10, 2023 · 41 d after period end